HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hanwha Chemical Corp.

Division of Hanwha Group
hcc.hanwha.co.kr

Latest From Hanwha Chemical Corp.

Interview: Fledgling ABL Bio And Its Global Ambitions In Bispecific Antibodies

South Korea’s ABL Bio is tackling cancer and neurodegenerative diseases with its broad bispecific antibody pipeline and CEO Sang Hoon Lee outlines the firm’s multi-collaboration and licensing strategy.

Research & Development South Korea

Korea Mulls New Biosimilar Guidelines As Pipeline Surges

As more biosimilar products are set to be released in South Korea, with a hefty number of ongoing late-stage clinical trials, the country is seeking to introduce a new separate guideline for insulin biosimilars. While South Korea has introduced biosimilar guidelines relatively earlier than some others, a local institute suggests these still need to be improved, pointing to a lack of clarity and implementation issues.

BioPharmaceutical South Korea

Korean Green Light For Samsung Bioepis’s Biosimilar Etanercept

Within just three and a half years since its establishment, Samsung Bioepis has received its first regulatory approval for a biosimilar, meaning the Samsung Group affiliate is now set to release its version of Amgen’s Enbrel (etanercept) in South Korea late this year or early next. It will be the fourth locally developed biosimilar to hit the domestic market and is expected to be priced at about a 30% discount.

BioPharmaceutical South Korea

Samsung Files Remicade Biosimilar In Europe

Following an approval filing for its Enbrel biosimilar candidate in the EU earlier this year, Samsung is now expanding its European biosimilar ambitions to Remicade.

BioPharmaceutical South Korea
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • South Korea
  • Parent & Subsidiaries
  • Hanwha Group
  • Senior Management
  • Ki Joon Hong, CEO
  • Contact Info
  • Hanwha Chemical Corp.
    Phone: 2 729 2700
    1 Janggyo-Dong
    Jung-Gu
    Seoul, 100-797
    South Korea
UsernamePublicRestriction

Register